3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination

SHANGHAI - Chinese biotech outfit 3SBio reported strong sales growth of its key products, recombinant human erythropoietin injection EPIAO and recombinant human thrombopoietin injection TPIAO, but like many companies in China, 3SBio's development plans are impacted by a regulatory slowdown caused by restructuring at China's State FDA